News headlines about Neothetics (NASDAQ:NEOT) have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neothetics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.4282693685848 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Neothetics (NASDAQ NEOT) traded down 2.7021% during mid-day trading on Friday, hitting $0.4573. 238,000 shares of the stock traded hands. Neothetics has a 1-year low of $0.30 and a 1-year high of $2.63. The company’s market capitalization is $6.33 million. The company’s 50-day moving average price is $0.38 and its 200 day moving average price is $1.18.

Neothetics (NASDAQ:NEOT) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.20). Equities research analysts forecast that Neothetics will post ($0.61) EPS for the current fiscal year.

Separately, ValuEngine downgraded shares of Neothetics from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 27th.

ILLEGAL ACTIVITY NOTICE: “Neothetics (NEOT) Earns Daily News Sentiment Rating of 0.17” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.